Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib

In clinical trials testing abemaciclib in patients with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer, diarrhea is a very common adverse event (occurring in approximately 85% of patients, any grade). Nonetheless, this toxicity leads to abemaciclib discontinuation in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Flavia, Agostinetto, Elisa, Solferino, Alessandra, Torrisi, Rosalba, Masci, Giovanna, Santoro, Armando, De Sanctis, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003298/
https://www.ncbi.nlm.nih.gov/pubmed/36902563
http://dx.doi.org/10.3390/jcm12051775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003298/
https://www.ncbi.nlm.nih.gov/pubmed/36902563
http://dx.doi.org/10.3390/jcm12051775

Ejemplares similares